PHASE II TRIAL OF R115777 IN PATIENTS WITH METASTATIC MALIGNANT MELANOMA
Overview
- Phase
- Phase 2
- Intervention
- tipifarnib
- Conditions
- Recurrent Melanoma
- Sponsor
- National Cancer Institute (NCI)
- Enrollment
- 40
- Locations
- 1
- Primary Endpoint
- Response rate (complete response [CR] and partial response [PR]}
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
This phase II trial is studying how well tipifarnib works in treating patients with metastatic malignant melanoma. Tipifarnib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.
Detailed Description
PRIMARY OBJECTIVES: I. To estimate the clinical response rate in patients with metastatic malignant melanoma treated with R115777 (tipifarnib). II. To evaluate the safety of R115777 in patients with metastatic melanoma. SECONDARY OBJECTIVES: I. To assess RhoC expression in tumor samples pre- and post- therapy with R115777. II. To evaluate Ftase levels in peripheral blood and tumor samples pre- and post-therapy with R115777. III. To assess the effect of R115777 treatment on T lymphocyte cytokine production, pre- and post- therapy with R115777. IV. Estimate time to treatment failure (TTF). Time to treatment failure is defined as time to withdrawal for unacceptable toxicity or progressive disease. OUTLINE Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve complete response (CR) receive 2 additional courses beyond CR. Patients who discontinue therapy due to toxicity or complete response are followed every 3 months for 2 years after study entry. Patients who discontinue therapy due to disease progression are followed every 6 months for 2 years after study entry. Patients with stable or partially responding disease who complete treatment are followed at 2 years after study entry.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histological or cytological diagnosis of cutaneous melanoma and clinical evidence of distant metastatic, non-resectable regional lymphatic, or extensive in transit recurrent disease
- •Patients must have at least 2 cutaneous lesions amenable to excisional biopsy for correlative studies; in addition, patients must have measurable disease; the disease remaining after the first excisional biopsy must be measurable; lesions that are considered intrinsically non-measurable include the following:
- •Bone lesions
- •Leptomeningeal disease
- •Pleural/pericardial effusion
- •Lymphangitis cutis/pulmonis
- •Abdominal masses that are not confirmed and followed by imaging techniques
- •Cystic lesions
- •Lesions that are situated in a previously irradiated area
- •No history of brain metastases
Exclusion Criteria
- Not provided
Arms & Interventions
Treatment (tipifarnib)
Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
Intervention: tipifarnib
Treatment (tipifarnib)
Patients receive oral tipifarnib twice daily on days 1-21. Treatment repeats every 28 days for at least 2 courses and for a maximum of 2 years in the absence of disease progression or unacceptable toxicity. Patients who achieve CR receive 2 additional courses beyond CR.
Intervention: laboratory biomarker analysis
Outcomes
Primary Outcomes
Response rate (complete response [CR] and partial response [PR]}
Time Frame: Up to 2 years
Estimated confidence intervals will be adjusted for the number of stages.
Progression-free survival (PFS)
Time Frame: From date of entry onto the trial until documented progression or death from any cause, assessed up to 2 years
Estimated using the method of Kaplan and Meier.
Time to treatment failure (TTF)
Time Frame: From trial entry until a patient ends protocol therapy due to unacceptable toxicity, progression or death from any cause, assessed up to 2 years
Estimated using the method of Kaplan and Meier.
Secondary Outcomes
- Correlation between RhoC expression levels and response(From baseline to up to 2 years)
- Change in FTAse levels(From baseline to up to 2 years)
- Change in the production of IL-2 and IFN-g by T cells(From baseline to up to 2 years)
- Adverse events as assessed by Common Toxicity Criteria (CTC) version 2.0(Up to 2 years)